ACAD - アカディア・ファ―マシュ―ティカルズ (ACADIA Pharmaceuticals Inc.) アカディア・ファ―マシュ―ティカルズ

 ACADのチャート


 ACADの企業情報

symbol ACAD
会社名 Acadia Pharmaceuticals Inc (アカディア・ファ―マシュ―ティカルズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 アカディア・ファーマシューティカルズ(ACADIA Pharmaceuticals Inc.)は神経と関連の中枢神経系疾患における満たされていない医療ニーズに応じた小分子薬事業を中心とするバイオ医薬品会社。同社は第III相開発段階におけるパーキンソン病精神病のためのファーストインクラスの治療薬である「pimavanserin」を含む4種類の製品候補を有する。同社は「pimavanserin」に対してグローバルな販売権を持つ。更に、同社はAllergan Inc.と連携して開発する慢性痛治療用の第II相試験にある薬品候補及び緑内障治療用の第I相試験にある薬品候補を有し、並びにMeiji Seika Kaisha Ltdと連携して開発する統合失調症治療用第I相開発段階における薬品候補も有する。同社の臨床段階における薬品候補は「Pimavanserin」、「Alpha Adrenergic Agonists」、「Muscarinic Agonist」と「AM-831」を含む。  アカディア・ファ―マシュ―ティカルズは、米国のバイオ医薬品会社。神経および関連中枢神経系疾患に対する治療薬に焦点を当て、主に、パ―キンソン病、精神分裂病、神経痛、アルツハイマ―病などの治療に関係する治療薬候補を開発する。本社は、カリフォルニア州サンディエゴ。   ACADIA Pharmaceuticals, Inc. operates as a biopharmaceutical company focused on the development and commercialization of medicines to address unmet medical needs in central nervous system, or CNS, disorders. It operates through development and commercialization of innovative medicines segment. The company was founded by Mark R. Brann on July 16, 1993 and is headquartered in San Diego, CA.
本社所在地 3611 Valley Centre Drive Suite 300 San Diego CA 92130 USA
代表者氏名 Stephen R. Biggar スティーブン・R・ビガール
代表者役職名 Independent Chairman of the Board
電話番号 +1 858-558-2871
設立年月日 34151
市場名 NASDAQ National Market System
ipoyear 2004年
従業員数 425人
url www.acadia-pharm.com
nasdaq_url https://www.nasdaq.com/symbol/acad
adr_tso
EBITDA EBITDA(百万ドル) -251.19800
終値(lastsale) 21.11
時価総額(marketcap) 2638891922.53
時価総額 時価総額(百万ドル) 2645.142
売上高 売上高(百万ドル) 185.07100
企業価値(EV) 企業価値(EV)(百万ドル) 2388.287
当期純利益 当期純利益(百万ドル) -182.79200
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 ACADIA Pharmaceuticals Inc. revenues increased from $45.8M to $105.9M. Net loss decreased 24% to $117.6M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Interest income net increase of 25% to $2.4M (income). Basic Earnings per Share excluding Extraordinary Items increased from -$1.27 to -$0.94.

 ACADのテクニカル分析


 ACADのニュース

   ACADIA Pharmaceuticals to Present at the 38th Annual J.P. Morgan Healthcare Conference on January 14, 2020  2020/01/07 14:00:00 Business Wire
SAN DIEGO--(BUSINESS WIRE)--ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 14, 2020, at 10:00 a.m. Pacific Time, followed by a question and answer breakout session. A live webcast of ACADIA’s presentation
   Has ACADIA Pharmaceuticals (ACAD) Outpaced Other Medical Stocks This Year?  2019/12/23 16:30:09 Zacks Investment Research
Is (ACAD) Outperforming Other Medical Stocks This Year?
   ACADIA Pharmaceuticals Appoints Stephanie Fagan as Senior Vice President, Corporate Affairs and Chief Communications Officer  2019/12/18 21:05:00 Business Wire
SAN DIEGO--(BUSINESS WIRE)--ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that Stephanie Fagan has been appointed to the newly created position of Senior Vice President, Corporate Affairs and Chief Communications Officer. Ms. Fagan will be responsible for all corporate communications and serve as a member of the company’s Executive Management Committee. She will report to Elena Ridloff, CFA, Executive Vice President, Chief Financial Officer of ACADIA. “Stephanie brings extensive ex
   The Daily Biotech Pulse: Cassava Gains On Alzheimer's Presentation, Bristol-Myers Hikes Dividend  2019/12/06 12:39:38 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on Dec. 5) ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD )(presented positive Phase 3 data for pimavanserin in dementia-related psychosis) Allergan plc (NYSE: AGN ) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) Applied Therapeutics Inc (NASDAQ: APLT ) Aurinia Pharmaceuticals Inc (NASDAQ: AUPH )( reported positive readout for a pivotal trial in volcosporin for lupus nephritis) Bristol-Myers Squibb Co (NYSE: BMY ) Cassava Sciences Inc (NASDAQ: SAVA ) Cue Biopharma Inc (NASDAQ: CUE ) Deciphera Pharmaceuticals Inc (NASDAQ: DCPH ) DexCom, Inc. (NASDAQ: DXCM ) Flexion Therapeutics Inc (NASDAQ: FLXN ) GALAPAGOS NV/S ADR (NASDAQ: GLPG ) Global Blood Therapeutics Inc (NASDAQ: GBT ) Incyte Corporation (NASDAQ: INCY ) Merck & Co., Inc. (NYSE: MRK ) Morphosys Ag (NASDAQ: MOR ) NuVasive, Inc. (NASDAQ: NUVA ) Oyster Point Pharma Inc (NASDAQ: OYST ) PTC Therapeutics, Inc.
   Biotech Stocks Are Making Wild Moves Amid a Deluge of Trial Data  2019/12/05 15:08:00 Barron's
Drug-trial news sent Aurinia and Acadia Pharmaceuticals soaring this morning and Sage Pharmaceuticals tumbling in early trading.
   Has ACADIA Pharmaceuticals (ACAD) Outpaced Other Medical Stocks This Year?  2019/12/23 16:30:09 Zacks Investment Research
Is (ACAD) Outperforming Other Medical Stocks This Year?
   ACADIA Pharmaceuticals Appoints Stephanie Fagan as Senior Vice President, Corporate Affairs and Chief Communications Officer  2019/12/18 21:05:00 Business Wire
SAN DIEGO--(BUSINESS WIRE)--ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that Stephanie Fagan has been appointed to the newly created position of Senior Vice President, Corporate Affairs and Chief Communications Officer. Ms. Fagan will be responsible for all corporate communications and serve as a member of the company’s Executive Management Committee. She will report to Elena Ridloff, CFA, Executive Vice President, Chief Financial Officer of ACADIA. “Stephanie brings extensive ex
   The Daily Biotech Pulse: Cassava Gains On Alzheimer's Presentation, Bristol-Myers Hikes Dividend  2019/12/06 12:39:38 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on Dec. 5) ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD )(presented positive Phase 3 data for pimavanserin in dementia-related psychosis) Allergan plc (NYSE: AGN ) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) Applied Therapeutics Inc (NASDAQ: APLT ) Aurinia Pharmaceuticals Inc (NASDAQ: AUPH )( reported positive readout for a pivotal trial in volcosporin for lupus nephritis) Bristol-Myers Squibb Co (NYSE: BMY ) Cassava Sciences Inc (NASDAQ: SAVA ) Cue Biopharma Inc (NASDAQ: CUE ) Deciphera Pharmaceuticals Inc (NASDAQ: DCPH ) DexCom, Inc. (NASDAQ: DXCM ) Flexion Therapeutics Inc (NASDAQ: FLXN ) GALAPAGOS NV/S ADR (NASDAQ: GLPG ) Global Blood Therapeutics Inc (NASDAQ: GBT ) Incyte Corporation (NASDAQ: INCY ) Merck & Co., Inc. (NYSE: MRK ) Morphosys Ag (NASDAQ: MOR ) NuVasive, Inc. (NASDAQ: NUVA ) Oyster Point Pharma Inc (NASDAQ: OYST ) PTC Therapeutics, Inc.
   Biotech Stocks Are Making Wild Moves Amid a Deluge of Trial Data  2019/12/05 15:08:00 Barron's
Drug-trial news sent Aurinia and Acadia Pharmaceuticals soaring this morning and Sage Pharmaceuticals tumbling in early trading.
   ACADIA Pharmaceuticals Presents Positive Top-line Results from Pivotal Phase 3 HARMONY Trial of Pimavanserin in Patients with Dementia-Related Psychosis at 12th Clinical Trials on Alzheimer’s Disease (CTAD) Meeting  2019/12/05 01:45:00 Business Wire
SAN DIEGO--(BUSINESS WIRE)--ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today presented positive top-line results from its Phase 3 HARMONY study at the 12th Clinical Trials on Alzheimer’s Disease (CTAD) Meeting, December 4 -7, 2019 in San Diego, California. HARMONY was a double-blind, placebo-controlled, relapse prevention study in 392 patients evaluating pimavanserin for the treatment of dementia-related psychosis. Pimavanserin met the primary endpoint of the study and was stopped at the pre-pl

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 アカディア・ファ―マシュ―ティカルズ ACAD ACADIA Pharmaceuticals Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)